|
LN-145 Clinical Trials
3 actively recruiting trials across 3 locations
Also known as: Autologous Tumor Infiltrating Lymphocytes, TIL, Autologous Tumor Infiltrating Lymphocytes, TIL, autologous tumor infiltrating lymphocytes
Pipeline
Phase 2: 3
Top Sponsors
- Iovance Biotherapeutics, Inc.2
- Karam Khaddour, MD, MS1
Indications
- Cancer3
- Lung Cancer2
- Metastatic Cutaneous Squamous Cell Carcinoma1
- Squamous Cell Carcinoma of the Head and Neck1
- Skin Cancer1
Duarte, California1 trial
Phase 2
La Jolla, California1 trial
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
University of California, San Diego
Phase 2
Boston, Massachusetts1 trial
TIL Therapy in cSCC and MCC
Dana-Farber Cancer Institute
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.